Immune-checkpoint targeted therapy using cytotoxic T lymphocyte-associated protein 4 (CTLA4), programmed cell death protein 1(PD-1) and programmed cell death ligand-1(PD-L1) inhibitors to overcome immune tolerance TOWARD cancer cells has been one of the major breakthrough in cancer therapy (1). The gene discussed is CTLA4; the disease is cancer.